Filtering by:
Cancer UpdatesMany Cancer Survivors Struggle to Pay For Care
The population of cancer survivors in the US is growing, and many struggle to pay health care costs. A study led by the Centers for Disease Control and Prevention (CDC) finds one-fourth of survivors have problems paying medical bills and one-third worry about them.
FDA Approves Keytruda (Pembrolizumab) for Head and Neck Cancer
The US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line treatment for people with advanced head and neck cancer.
FDA Approves Polivy (Polatuzumab Vedotin-piiq) for Lymphoma
The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) to treat people with diffuse large B-cell lymphoma (DLBCL).
Population of US Cancer Survivors Grows to Nearly 17 Million
A new report by the American Cancer Society – in collaboration with the National Cancer Institute – estimates there are more than 16.9 million cancer survivors alive in the US today, and that number will grow to more than 22.1 million by 2030.
Cancer Specialists Gather to Discuss Innovations in Research and Treatment
More than 39,000 cancer specialists from around the world are gathering in Chicago this week for the 55th annual meeting of the American Society of Clinical Oncology (ASCO).
Annual Report to the Nation: Cancer Death Rate Continues Decades-long Decline
The death rate from cancer in the United States is still falling among men, women, and children, according to the latest Annual Report to the Nation on the Status of Cancer, 1999–2015. Overall rates of new cancers decreased in men from 1999 to 2015 and were stable in women during this time.
FDA Approves First PI3K Inhibitor for Breast Cancer
The US Food and Drug Administration (FDA) has approved the first treatment of its kind for a certain type of breast cancer caused by an inherited genetic mutation. Piqray (alpelisib) is a targeted therapy called a PI3K inhibitor.
Lesbian, Gay, and Bisexual Cancer Survivors Face Challenges
Lesbian, gay, bisexual, and other non-heterosexual cancer survivors have a lower quality of life than heterosexual cancer survivors, according to a study by Boston University and Harvard University researchers.
